ATRenew revenue jumps 25.3% to RMB6.45 billion
ATRenew (NYSE:RERE) reported a 25.3% year-over-year increase in third-quarter 2026 net revenue to RMB6,452.9 million, alongside higher operating income and net profit.
ATRenew (NYSE:RERE) reported a 25.3% year-over-year increase in third-quarter 2026 net revenue to RMB6,452.9 million, alongside higher operating income and net profit.
Oil prices were little changed on Thursday as expectations of a global supply surplus and higher US interest rates offset concerns about Middle East supply disruptions following attacks on shipping in the Strait of Hormuz.
HUTCHMED (NASDAQ:AIM:HCM) reported positive preclinical results for HMPL-A830, an experimental cancer treatment designed to target EGFR and KRAS signalling, at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Barcelona.
Immutep (NASDAQ:IMMP) reported encouraging survival results from its Phase II EFTISARC-NEO trial, with an estimated 81.1% disease-free survival rate at 12 months among patients with high-risk, resectable soft tissue sarcoma.
JOYY (NASDAQ:JOYY) reported third-quarter 2026 revenue of $624.6 million, up 15.6% year over year, as its Social Entertainment, BIGO Ads and SHOPLINE businesses recorded higher revenue for the quarter ended September 30, 2026.
Evotec SE (NASDAQ:EVO) announced that the U.S. Food and Drug Administration (FDA) has accepted a second Investigational New Drug (IND) application under its strategic protein degradation partnership with Bristol Myers Squibb (NYSE:BMY), advancing another experimental drug candidate toward clinical development.
K3 Capital’s sBOLD vault lost its entire $3.42 million balance on Ethereum on 18 November.
US Senators Cynthia Lummis, Kirsten Gillibrand, Angela Alsobrooks, Kevin Cramer, Pete Ricketts and Mark Warner have urged Treasury to protect state-regulated payment stablecoin issuers through a proposed safe harbour.
StraitsX, Oversea-Chinese Banking Corporation Limited (SGX:O39) and Standard Chartered PLC (LSE:STAN) have completed a cross-bank payment test involving tokenised deposits.
Argenica Therapeutics (ASX:AGN) says the US Food and Drug Administration (FDA) has kept a clinical hold on its US trial plans for stroke drug xaranetide, and has asked for an additional rat study before any US patients can be dosed.
GARANTA JÁ SEU GRAFA EDGE
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade
